Evolva completes Abunda acquisition
Evolva Holding SA announced that it completed the acquisition of Abunda Nutrition, Inc. , after which it will be a wholly-owned subsidiary of Evolva.
Evolva’s shareholders approved the capital increase required for the acquisition in the Annual General Meeting (“AGM”) of Evolva on 18 May 2011. As announced on 5 April 2011, the acquisition of Abunda requires an upfront investment of 25 million newly issued Evolva shares. This equals close to 18% of Evolva’s currently outstanding capital. SIX Swiss Exchange has cleared the Listing Prospectus related to the issue of the new Evolva shares so that the transaction could be executed.
The selling Abunda shareholders have agreed to submit the Evolva shares they will receive, to the Lock-up and Coordinated Sale mechanism. This structure was set up by Evolva’s core investors in December 2010 in order to facilitate the gradual release of Evolva’s lock-up and increase the stock’s free-float.
Evolva’s shareholders elected two new members for the Board of Directors in the AGM of 18 May 2011: Ganesh Kishore and Stuart Strathdee. The election was conditional upon the closing of the Abunda acquisition. Upon closing, the election of the two Board members will be confirmed. In addition, the CEO of Abunda, Simon Waddington, will join Evolva’s Group Management Team.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Tripos Announces LeadScreen™ 2002, Pre-Formatted Screening Compound Set to Accelerate Drug Discovery by Biotechs
Inion introduces its First Biodegradable Spinal Implant in Europe - CE Mark received for S-1TM Anterior Cervical Fixation System
Dr Barry Buckland Joins the Mucosis Supervisory Board
Beckman Coulter Announces the Creation of Beckman Coulter Genomics - New Company Offers Comprehensive Genomic Services
Scientists remove amyloid plaques from brains of live animals with Alzheimer's disease - New research in the FASEB Journal suggests that manipulation of the brain's own immune cells with IL-6 could lead to reversal of Alzheimer's disease pathology
